Endolymphatic hydrops

Summary

Endolymphatic hydrops (MONDO:0006744) is a disease and 5 clinical trials. Top therapeutic interventions include terfenadine. A subtype of peripheral vertigo — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 5

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	endolymphatic hydrops
Mondo ID	MONDO:0006744
EFO	EFO:1000918
MeSH	D018159
DOID	DOID:9848
SNOMED CT	27621000119100
UMLS	C0206586
MedGen	60183
MedDRA	10049934
Is cancer (heuristic)	no

Disease family

This is a subtype of peripheral vertigo. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › auditory system disorder › inner ear disorder › vestibular disorder › peripheral vertigo › endolymphatic hydrops

Related subtypes (3): vertigo, benign recurrent, 2, benign paroxysmal positional vertigo, vertigo, benign recurrent, 1

Subtypes (1): Meniere disease

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 5.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	5

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06910865	Not specified	RECRUITING	Study of the Radio-clinical Correlation of Endolymphatic Hydrops
NCT01661777	Not specified	WITHDRAWN	Refractory Eustachian Tube Dysfunction: Are the Symptoms Related to Endolymphatic Hydrops
NCT03132961	Not specified	TERMINATED	Effects of Infrasound Exposure on Measures of Endolymphatic Hydrops
NCT03215420	Not specified	COMPLETED	Comparison of 3 Methods to Diagnose Endolymphatic Hydrops in Meniere’s Disease
NCT05229744	Not specified	TERMINATED	Prevalence of Endolymphatic Hydrops With a Hitory of Congenital Cytomegalovirus Infection

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
TERFENADINE	4	1